Phase II study of E7070 in patients with metastatic melanoma. |
| |
| Authors: | J F Smyth S Aamdal A Awada C Dittrich F Caponigro P Sch?ffski M Gore T Lesimple N Djurasinovic B Baron M Ravic P Fumoleau C J A Punt |
| |
| Affiliation: | University of Edinburgh, Cancer Research Centre, Western General Hospital, Edinburgh, UK. john.smyth@cancer.org.uk |
| |
| Abstract: | E7070 is a synthetic chloro-indolyl sulphonamide that is being developed as an anti cancer agent. In this phase II study, 28 patients with metastatic melanoma received 700 mg/m(2) of E7070 as a 60-min infusion repeated every 3 weeks. Although therapy was well tolerated, with one patient receiving 14 courses of treatment, there were only minor responses on independent radiological review. E7070 does not warrant further development as a single agent for the treatment of metastatic melanoma. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect Oxford 等数据库收录！ |
|
